MedSurg and Neurotechnology — Reclassification to: cost of sales
Stryker MedSurg and Neurotechnology — Reclassification to: cost of sales increased by 0.8% to $1.43B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.6%, from $1.31B to $1.43B. Over 2 years (FY 2022 to FY 2024), MedSurg and Neurotechnology — Reclassification to: cost of sales shows an upward trend with a 7.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase in reclassified costs may compress gross margins, while a decrease suggests improved cost allocation or operational efficiency.
Detailed definition
Captures specific expenses or costs previously categorized elsewhere that have been reallocated to the cost of sales for...
Peer comparison
Common in companies with complex accounting adjustments or evolving cost-accounting standards.
syk_segment_medsurg_and_neurotechnology_reclassification_to_cost_of_salesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.16B | $1.16B | $1.16B | $1.16B | $1.22B | $1.22B | $1.22B | $1.22B | $1.24B | $1.29B | $1.31B | $1.48B | $1.32B | $1.41B | $1.43B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.2% | +0.0% | +0.0% | +0.0% | +1.6% | +4.0% | +2.0% | +12.9% | -10.9% | +7.0% | +0.8% |
| YoY Change | — | — | — | — | +5.2% | +5.2% | +5.2% | +5.2% | +1.6% | +5.6% | +7.7% | +21.6% | +6.7% | +9.9% | +8.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology — reclassification to: cost of sales?
- Stryker (SYK) reported medsurg and neurotechnology — reclassification to: cost of sales of $1.43B in Q3 2025.
- How has Stryker's medsurg and neurotechnology — reclassification to: cost of sales changed year-over-year?
- Stryker's medsurg and neurotechnology — reclassification to: cost of sales increased by 8.6% year-over-year, from $1.31B to $1.43B.
- What is the long-term trend for Stryker's medsurg and neurotechnology — reclassification to: cost of sales?
- Over 2 years (2022 to 2024), Stryker's medsurg and neurotechnology — reclassification to: cost of sales has grown at a 7.1% compound annual growth rate (CAGR), from $4.64B to $5.32B.
- What does medsurg and neurotechnology — reclassification to: cost of sales mean?
- Costs moved into the cost of goods sold category to better reflect direct production expenses.